AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals

AstraZeneca‘s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge in total revenue, reaching $54.1 billion. This growth was underpinned by the strong performance of its oncology and biopharmaceutical portfolios, alongside a strategic focus on expanding its rare disease treatments. Core earnings per share (EPS) climbed